IL174591A0 - Composition and dosage form for sustained effect of levodopa - Google Patents
Composition and dosage form for sustained effect of levodopaInfo
- Publication number
- IL174591A0 IL174591A0 IL174591A IL17459106A IL174591A0 IL 174591 A0 IL174591 A0 IL 174591A0 IL 174591 A IL174591 A IL 174591A IL 17459106 A IL17459106 A IL 17459106A IL 174591 A0 IL174591 A0 IL 174591A0
- Authority
- IL
- Israel
- Prior art keywords
- levodopa
- composition
- dosage form
- sustained effect
- sustained
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51297303P | 2003-10-20 | 2003-10-20 | |
| PCT/US2004/034121 WO2005042101A1 (en) | 2003-10-20 | 2004-10-14 | Composition and dosage form for sustained effect of levodopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL174591A0 true IL174591A0 (en) | 2006-08-20 |
Family
ID=34549241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL174591A IL174591A0 (en) | 2003-10-20 | 2006-03-27 | Composition and dosage form for sustained effect of levodopa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050113452A1 (enExample) |
| EP (1) | EP1675651A1 (enExample) |
| JP (1) | JP2007509146A (enExample) |
| KR (2) | KR100894465B1 (enExample) |
| AU (1) | AU2004285436C1 (enExample) |
| CA (1) | CA2553156A1 (enExample) |
| EA (1) | EA200600626A1 (enExample) |
| IL (1) | IL174591A0 (enExample) |
| MX (1) | MXPA06004327A (enExample) |
| NZ (1) | NZ546662A (enExample) |
| WO (1) | WO2005042101A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| DE10214188B4 (de) | 2002-03-28 | 2005-08-25 | Siemens Ag | Verfahren zur gesicherten Übertragung von Daten, insbesondere zur Übertragung über eine Luftschnittstelle |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| BRPI0513598A (pt) * | 2004-07-26 | 2008-05-13 | Teva Pharma | formas de dosagem em comprimidos revestidos de liberação entérica |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US20070027216A1 (en) * | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| WO2007056570A2 (en) * | 2005-11-07 | 2007-05-18 | Teva Pharmaceutical Industries Ltd. | Levodopa compositions |
| KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파／칼비도파의 ２４시간의 장기간 장내투여 |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| IT202000019303A1 (it) | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| EP4316482A1 (en) * | 2022-08-01 | 2024-02-07 | 4P-Pharma | Levodopa for preventing addiction |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779500T2 (de) * | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4716246A (en) * | 1986-08-22 | 1987-12-29 | Merck & Co., Inc. | Process for L-dopa |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5041430A (en) * | 1989-09-18 | 1991-08-20 | Du Pont Mereck Pharmaceutical Company | Oral anticoagulant/platelet inhibitor low dose formulation |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| US6117453A (en) * | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| JP2004501190A (ja) * | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| JP4426286B2 (ja) * | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| EA006053B1 (ru) * | 2001-12-24 | 2005-08-25 | Тева Фармасьютикал Индастриес Лтд. | Твёрдая лекарственная форма, способ её изготовления и устройство |
-
2004
- 2004-10-14 JP JP2006536678A patent/JP2007509146A/ja active Pending
- 2004-10-14 EP EP04795307A patent/EP1675651A1/en not_active Withdrawn
- 2004-10-14 KR KR1020067009822A patent/KR100894465B1/ko not_active Expired - Fee Related
- 2004-10-14 WO PCT/US2004/034121 patent/WO2005042101A1/en not_active Ceased
- 2004-10-14 KR KR1020087029777A patent/KR20080109101A/ko not_active Ceased
- 2004-10-14 NZ NZ546662A patent/NZ546662A/en unknown
- 2004-10-14 US US10/966,090 patent/US20050113452A1/en not_active Abandoned
- 2004-10-14 EA EA200600626A patent/EA200600626A1/ru unknown
- 2004-10-14 MX MXPA06004327A patent/MXPA06004327A/es unknown
- 2004-10-14 AU AU2004285436A patent/AU2004285436C1/en not_active Ceased
- 2004-10-14 CA CA002553156A patent/CA2553156A1/en not_active Abandoned
-
2006
- 2006-03-27 IL IL174591A patent/IL174591A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004285436A1 (en) | 2005-05-12 |
| KR20070085032A (ko) | 2007-08-27 |
| EA200600626A1 (ru) | 2007-02-27 |
| KR20080109101A (ko) | 2008-12-16 |
| KR100894465B1 (ko) | 2009-04-22 |
| AU2004285436B2 (en) | 2009-01-08 |
| NZ546662A (en) | 2009-03-31 |
| WO2005042101A1 (en) | 2005-05-12 |
| WO2005042101A8 (en) | 2006-10-19 |
| MXPA06004327A (es) | 2007-01-26 |
| EP1675651A1 (en) | 2006-07-05 |
| JP2007509146A (ja) | 2007-04-12 |
| US20050113452A1 (en) | 2005-05-26 |
| AU2004285436C1 (en) | 2009-07-16 |
| CA2553156A1 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003259735A8 (en) | Small-mer compositions and methods of use | |
| EP1578403A4 (en) | MODIFIED RELEASE MILNACIPRANE COMPOSITIONS | |
| IL175314A0 (en) | Administration of levodopa and carbidopa | |
| IL218357A0 (en) | Compositions and methods of using angiopoietin-like 4 protein | |
| IL164370A0 (en) | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease | |
| HUP0303313D0 (en) | Transdermal pharmaceutical compositions | |
| AU2003220361A8 (en) | Benzamides and compositions benzamides for use as fungizide | |
| IL183986A0 (en) | Pharmaceutical compounds and compositions | |
| AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
| IL166608A0 (en) | Anti-microbial compositions and methods of using same | |
| GB0404327D0 (en) | Pharmaceutical composition and method of using same | |
| HU0302441D0 (en) | Pharmaceutical compositions having antibiothic effect | |
| GB0615918D0 (en) | Composition and its therapeutic use | |
| IL178067A0 (en) | Pharmaceutical dosage forms and compositions | |
| IL174144A0 (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
| SI1667693T1 (sl) | Sestave in postopki za uporabo lamelastih teles v terapevtske namene | |
| GB0324523D0 (en) | Compositions and methods of treatment | |
| AU2003294684A8 (en) | Ketoprofen compositions and methods of making them | |
| IL175746A0 (en) | Oral formulations of desoxypeganine and uses thereof | |
| EP1534293A4 (en) | INFLAMMATORY COMPOSITIONS AND METHODS OF ADMINISTRATION | |
| AU2003268078A8 (en) | Levothyroxine compositions and methods | |
| GB0327050D0 (en) | Therapeutic methods compositions and uses | |
| HK1093169A (en) | Composition and dosage form for sustained effect of levodopa | |
| GB0205826D0 (en) | Therapeutic compositions and methods | |
| IL177751A0 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use |